Colorectal Cancer Screening Scale is a gender-specific instrument developed and validated to assess for barriers to colorectal cancer screening among men.

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival.